New Age Alpha Advisors LLC Takes Position in Medpace Holdings, Inc. (NASDAQ:MEDP)

New Age Alpha Advisors LLC purchased a new position in Medpace Holdings, Inc. (NASDAQ:MEDP - Free Report) in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 5,678 shares of the company's stock, valued at approximately $1,886,000.

Several other institutional investors and hedge funds have also bought and sold shares of the stock. Lindbrook Capital LLC grew its position in shares of Medpace by 27.6% in the 4th quarter. Lindbrook Capital LLC now owns 134 shares of the company's stock worth $45,000 after buying an additional 29 shares during the period. HBK Sorce Advisory LLC grew its holdings in Medpace by 0.5% in the fourth quarter. HBK Sorce Advisory LLC now owns 5,384 shares of the company's stock worth $1,789,000 after purchasing an additional 29 shares during the period. Assetmark Inc. increased its stake in shares of Medpace by 20.1% during the fourth quarter. Assetmark Inc. now owns 173 shares of the company's stock valued at $57,000 after purchasing an additional 29 shares in the last quarter. Proficio Capital Partners LLC lifted its holdings in shares of Medpace by 4.1% during the fourth quarter. Proficio Capital Partners LLC now owns 730 shares of the company's stock valued at $243,000 after purchasing an additional 29 shares during the last quarter. Finally, Schulhoff & Co. Inc. boosted its position in shares of Medpace by 1.2% in the 4th quarter. Schulhoff & Co. Inc. now owns 2,630 shares of the company's stock worth $874,000 after purchasing an additional 30 shares in the last quarter. 77.98% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

A number of equities research analysts have recently commented on MEDP shares. Leerink Partners assumed coverage on Medpace in a research note on Monday, March 24th. They issued a "market perform" rating and a $330.00 target price on the stock. Robert W. Baird increased their price objective on shares of Medpace from $354.00 to $362.00 and gave the company a "neutral" rating in a research report on Monday, January 27th. Finally, Leerink Partnrs raised shares of Medpace to a "hold" rating in a report on Monday, March 24th. Nine equities research analysts have rated the stock with a hold rating and five have assigned a buy rating to the company. According to data from MarketBeat, Medpace has an average rating of "Hold" and a consensus target price of $376.30.

Remove Ads

Medpace Stock Performance

Shares of Medpace stock traded down $17.00 on Friday, hitting $287.11. 833,195 shares of the company's stock were exchanged, compared to its average volume of 307,368. Medpace Holdings, Inc. has a 1 year low of $283.24 and a 1 year high of $459.77. The company has a 50-day simple moving average of $331.56 and a 200-day simple moving average of $337.60. The stock has a market capitalization of $8.75 billion, a PE ratio of 22.73, a PEG ratio of 3.81 and a beta of 1.45.

Medpace (NASDAQ:MEDP - Get Free Report) last released its earnings results on Monday, February 10th. The company reported $3.67 EPS for the quarter, topping analysts' consensus estimates of $2.96 by $0.71. Medpace had a net margin of 19.17% and a return on equity of 51.48%. On average, analysts expect that Medpace Holdings, Inc. will post 12.29 EPS for the current fiscal year.

Medpace Profile

Medpace Holdings, Inc engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. Its services include medical department, clinical trial management, data-driven feasibility, study-start-up, clinical monitoring, regulatory affairs, patient recruitment and retention, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory, laboratories, clinics, and quality assurance.